文献速递艾滋病与性传播感染

出生第一周内启动抗逆转录病毒治疗的安全性与有效性

Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life.
PubMed 文献 · Clin Infect Dis · 2021-01-01

博茨瓦纳早期婴儿治疗研究在出生96小时内检测HIV暴露婴儿,HIV感染婴儿在出生<7天启动奈韦拉平/齐多夫定/拉米夫定。40名婴儿中位2天龄启动,奈韦拉平谷浓度波动大且50%的2周测量低于治疗目标,但方案安全有效,12周55%病毒载量<40拷贝/mL,24周71%<40拷贝/mL。

要点

  • 出生第一周内启动NVP/ZDV/3TC方案安全有效,即使NVP谷浓度低于目标。
  • 12周55%婴儿HIV RNA<40拷贝/mL,24周71%<40拷贝/mL。
  • 过渡到LPV/r后22.5%出现短暂病毒载量升高,可能与LPV/r口感差有关。

核心结论

  • 出生第一周内启动NVP/ZDV/3TC安全有效,即使NVP谷浓度低于治疗目标;过渡到LPV/r后出现短暂病毒升高,但12和24周多数儿童实现并维持病毒抑制。

研究设计与样本

  • 博茨瓦纳早期婴儿治疗研究,在出生96小时内检测HIV暴露婴儿,HIV感染婴儿在出生<7天启动NVP 6 mg/kg每日两次、ZDV和3TC。
  • 40名HIV感染婴儿中位启动年龄2天(范围1-5天),在1和2周检测NVP谷浓度,并根据出生胎龄在2、3、4或5周将NVP转换为洛匹那韦/利托那韦(LPV/r)。

主要发现

  • NVP谷浓度高度可变,50%的2周测量低于治疗目标(3000 ng/mL),浓度与第2、4、12周病毒下降不相关。
  • 截至24周发生2例与ART无关的死亡,仅需1次非计划治疗调整。
  • 过渡到LPV/r后4周内,9例(22.5%)出现短暂HIV RNA升高,可能因LPV/r口感差。
  • 12周时40例中22例(55%)<40拷贝/mL(93%<400拷贝/mL);24周时38例中27例(71%)<40拷贝/mL(84%<400拷贝/mL)。
  • 12和24周HIV-1 RNA应答与基线HIV RNA或其他因素无关。

临床怎么用

  • 对于出生第一周内确诊HIV感染的婴儿,可考虑启动NVP/ZDV/3TC方案,即使NVP谷浓度低于目标仍可能有效。
  • 过渡到LPV/r时需警惕短暂病毒载量升高,并关注LPV/r口感问题对依从性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early antiretroviral therapy (ART) is recommended for infants with human immunodeficiency virus (HIV) infection. However, few antiretroviral options are available for neonates. METHODS: The Early Infant Treatment Study in Botswana tested HIV-exposed infants within 96 hours of birth, and HIV-infected infants started nevirapine (NVP) 6 mg/kg twice daily, zidovudine (ZDV), and lamivudine (3TC) at age < 7 days. NVP trough concentrations were tested at 1 and 2 weeks. NVP was switched to ritonavir-boosted lopinavir (LPV/r) at week 2, 3, 4, or 5 according to delivery gestational age. RESULTS: Forty HIV-infected infants started ART at median age 2 days (range, 1-5 days). NVP trough concentrations were highly variable and below therapeutic target (3000 ng/mL) for 50% of 2-week measurements; concentrations did not correlate with viral decline at weeks 2, 4, or 12. Two deaths unrelated to ART occurred through 24 weeks. Only 1 unscheduled treatment modification was required. Within 4 weeks of transition to LPV/r, 9 (22.5%) had transient HIV RNA increases, likely due to poor LPV/r palatability. At 12 weeks, 22 (55%) of 40 were <40 copies/mL (93% <400 copies/mL); by 24 weeks, 27 of 38 (71%) were < 40 copies/mL (84% < 400 copies/mL). HIV-1 RNA response at 12 and 24 weeks did not differ by baseline HIV RNA or other factors. CONCLUSIONS: NVP/ZDV/3TC started in the first week of life was safe and effective, even when trough NVP levels were below target. Transient viral increases occurred following transition to LPV/r, but by 12 and 24 weeks most children achieved and maintained viral suppression. CLINICAL TRIALS REGISTRATION: NCT02369406.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Maswabi K, Ajibola G, Bennett K, et al. Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life. Clin Infect Dis. 2021. PMID: 31927562. doi:10.1093/cid/ciaa028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。